Moderna achieves positive interim results from phase 3 trial of next-generation covid-19 vaccine

Mrna-1283 induced a more robust immune response compared to spikevax® covid-19 vaccine, mrna-1273.222 next-generation mrna vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and covid-19, mrna-1083 cambridge, ma / accesswire / march 26, 2024 / moderna, inc. (nasdaq:mrna) today announced that mrna-1283, the company's next-generation covid-19 vaccine, has successfully met the primary endpoints of its phase 3 clinical trial, demonstrating a higher immune response against sars-cov-2 when compared to mrna-1273.222, moderna's licensed covid-19 vaccine. "we are excited to announce our fourth infectious disease vaccine program with positive phase 3 data, further validating our robust mrna platform," said stÉphane bancel, chief executive officer of moderna.
MRNA Ratings Summary
MRNA Quant Ranking